157. Sturge-Weber syndrome Clinical trials / Disease details
Clinical trials : 10 / Drugs : 13 - (DrugBank : 4) / Drug target genes : 5 - Drug target pathways : 63
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05495269 (ClinicalTrials.gov) | November 23, 2022 | 2/8/2022 | Safety and Tolerability Study of QLS-101 in Adolescents With Sturge-Weber Syndrome (SWS)-Related Glaucoma Due to Elevated Episcleral Venous Pressure (EVP) | Pilot, Open-label Study of Safety and Tolerability of QLS-101 in Adolescents With Sturge-Weber Syndrome (SWS)-Related Glaucoma Due to Elevated Episcleral Venous Pressure (EVP) | Sturge-Weber Syndrome;Glaucoma;Ocular Hypertension | Drug: QLS-101 ophthalmic solution, 2.0 % | Qlaris Bio, Inc. | NULL | Active, not recruiting | 12 Years | 19 Years | All | 2 | Phase 2 | United States |
| 2 | NCT04999618 (ClinicalTrials.gov) | January 1, 2020 | 17/7/2021 | A New Approach in Laser Surgery Using the Regenerative Solution in Children Diagnosed With Vascular Pathology | DOUBLE-SKIN: a New Approach in Laser Surgery Using the Regenerative Solution in Children Diagnosed With Vascular Pathology: a Randomised, Double-blind, Placebo-controlled Trial | Vascular Diseases;Vascular Malformation;Capillary Malformation-Arteriovenous Malformation;Port-Wine Stain;Sturge-Weber Syndrome;Vascular Tumor | Drug: Haemoblock;Other: Placebo | Center for Vascular Pathology, Moscow | NULL | Completed | 6 Months | 18 Years | All | 200 | Phase 4 | Russian Federation |
| 3 | NCT04447846 (ClinicalTrials.gov) | October 14, 2019 | 10/10/2019 | Novel Cognitive Treatment Targets for Epidiolex in Sturge- Weber Syndrome | Novel Cognitive Treatment Targets for Epidiolex in Sturge- Weber Syndrome: A Phase II Trial | Sturge-Weber Syndrome | Drug: Cannabidiol | Anne Comi, MD | Jazz Pharmaceuticals;Faneca 66 Foundation | Completed | 3 Years | 50 Years | All | 10 | Phase 2 | United States |
| 4 | NCT03047980 (ClinicalTrials.gov) | January 2017 | 2/2/2017 | Trial of Sirolimus for Cognitive Impairment in Sturge-Weber Syndrome | Trial of Sirolimus for Cognitive Impairment in Sturge-Weber Syndrome | Sturge-Weber Syndrome | Drug: Sirolimus | Anne Comi, MD | Children's Hospital Medical Center, Cincinnati;Pfizer;National Institutes of Health (NIH);Faneca 66 Foundation;National Institute of Neurological Disorders and Stroke (NINDS) | Active, not recruiting | 3 Years | 31 Years | All | 10 | Phase 2/Phase 3 | United States |
| 5 | NCT02332655 (ClinicalTrials.gov) | December 2014 | 5/1/2015 | Cannabidiol Expanded Access Study in Medically Refractory Sturge-Weber Syndrome | Cannabidiol Expanded Access Study in Medically Refractory Sturge-Weber Syndrome | Sturge-Weber Syndrome | Drug: Cannabidiol | Anne Comi, MD | GW Pharmaceuticals Ltd.;Faneca 66 Foundation | Active, not recruiting | 1 Month | 45 Years | All | 5 | Phase 1/Phase 2 | United States |
| 6 | NCT01997255 (ClinicalTrials.gov) | April 2014 | 15/11/2013 | Adjunctive Everolimus (RAD 001) Therapy for Epilepsy in Children With Sturge-Weber Syndrome (SWS) | An Open-Label Controlled Study of Adjunctive Everolimus (RAD 001) Therapy for Epilepsy in Children With Sturge-Weber Syndrome | Sturge Weber Syndrome | Drug: Everolimus | Baylor College of Medicine | Novartis Pharmaceuticals | Withdrawn | 2 Years | 18 Years | Both | 0 | Phase 2 | United States |
| 7 | NCT01533376 (ClinicalTrials.gov) | February 2012 | 11/2/2012 | Treatment of Port-wine Mark in Sturge-Weber Syndrome Using Topical Timolol | Treatment of Port-wine Mark in Sturge-Weber Syndrome Using Topical Timolol | Sturge Weber Syndrome;Port-wine Mark | Drug: Timolol;Drug: Preservative free artificial tear gel. | Wills Eye | University of Medicine and Dentistry of New Jersey | Terminated | 2 Years | 10 Years | All | 3 | Phase 1 | United States |
| 8 | EUCTR2010-024078-20-ES (EUCTR) | 11/05/2011 | 15/12/2010 | Ensayo clínico fase II, aleatorizado, triple ciego, controlado intraindividualmente con placebo, para evaluar la eficacia y seguridad de la rapamicina tópica sola o asociada a láser de colorante pulsado en pacientes con síndrome de Sturge-Weber | Ensayo clínico fase II, aleatorizado, triple ciego, controlado intraindividualmente con placebo, para evaluar la eficacia y seguridad de la rapamicina tópica sola o asociada a láser de colorante pulsado en pacientes con síndrome de Sturge-Weber | Malformación capilar cutánea en pacientes con síndrome de Sturge-Weber. MedDRA version: 13;Level: PT;Classification code 10042265;Term: Síndrome de Sturge-Weber | Product Name: Rapamicina tópica al 1% y excipiente INN or Proposed INN: crema de rapamicina al 1% y excipientes Product Name: Crema placebo (excipiente) INN or Proposed INN: Crema placebo (excipiente) | Instituto Científico y Tecnológico de Navarra | NULL | Not Recruiting | Female: yes Male: yes | Spain | ||||
| 9 | NCT02080624 (ClinicalTrials.gov) | January 2011 | 18/4/2013 | Efficacy and Safety Study of Topical Rapamycin Associated With Pulsed Dye Laser in Patients With Sturge-Weber Syndrome | Phase II, Randomized, Triple Blind, Intra-individually Placebo-controlled Clinical Trial to Assess the Efficacy and Safety of Topical Rapamycin Associated With Pulsed Dye Laser in Patients With Sturge-Weber Syndrome. | Sturge- Weber Syndrome | Drug: Drug: Topical Rapamycin | Clinica Universidad de Navarra, Universidad de Navarra | NULL | Completed | 16 Years | 65 Years | Both | 23 | Phase 2 | Spain |
| 10 | NCT00639730 (ClinicalTrials.gov) | May 2006 | 14/3/2008 | Use of the Atkins Diet for Children With Sturge Weber Syndrome | Use of the Atkins Diet for Children With Sturge Weber Syndrome | Epilepsy;Sturge Weber Syndrome | Dietary Supplement: modified Atkins diet | Johns Hopkins University | Vascular Birthmarks Foundation | Completed | 2 Years | 18 Years | Both | 5 | Phase 1 | United States |